Like and c_老虎社区_美港股上老虎

Dennishyh
2021-09-29

Like and comment

3 Big Pharma Stocks Wall Street Thinks Could Soar By At Least 30%

Analysts expect one of them could skyrocket more than 40% over the next 12 months.

3 Big Pharma Stocks Wall Street Thinks Could Soar By At Least 30%

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":862129627,"tweetId":"862129627","gmtCreate":1632844940105,"gmtModify":1632844940236,"author":{"id":3579224673007813,"authorId":3579224673007813,"authorIdStr":"3579224673007813","name":"Dennishyh","avatar":"https://static.tigerbbs.com/79de7417eb609458d6cb6e72e515dadb","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":22,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Like and comment</p></body></html>","htmlText":"<html><head></head><body><p>Like and comment</p></body></html>","text":"Like and comment","highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":3,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/862129627","repostId":2170724186,"repostType":4,"repost":{"id":"2170724186","pubTimestamp":1632843061,"share":"https://www.laohu8.com/m/news/2170724186?lang=&edition=full","pubTime":"2021-09-28 23:31","market":"us","language":"en","title":"3 Big Pharma Stocks Wall Street Thinks Could Soar By At Least 30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2170724186","media":"Motley Fool","summary":"Analysts expect one of them could skyrocket more than 40% over the next 12 months.","content":"<p>Many investors like to buy shares of large drugmakers for the relative stability that they provide. But tremendous growth often isn't expected from these stocks.</p>\n<p>That doesn't mean, though, that strong growth is always out of the question for top biopharmaceutical companies.&nbsp;Here are three big pharma stocks that Wall Street thinks could soar by at least 30% within the next 12 months.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F644349%2Fanalysts-looking-at-stock-charts.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>1. Bristol Myers Squibb</h2>\n<p>The consensus Wall Street price target for&nbsp;<b>Bristol Myers Squibb</b> (NYSE:BMY) reflects a premium of nearly 34% to the current share price. Of the 22 analysts surveyed by Refinitiv, the most pessimistic of the group thinks that the pharma stock could jump at least 10% higher.</p>\n<p>This bullishness might be somewhat surprising. BMS' top-selling product, Revlimid, faces generic competition beginning next year. The blood cancer drug generated 27% of the company's total revenue in the second quarter.</p>\n<p>So why do analysts like BMS so much? For <a href=\"https://laohu8.com/S/AONE.U\">one</a> thing, that generic competition will only be in limited volumes at first thanks to contractual agreements. The company also has several other blockbusters with strong sales growth, notably including blood thinner Eliquis and cancer immunotherapies Opdivo and Yervoy.</p>\n<p>BMS' lineup is loaded with newer drugs with tremendous potential as well. Cancer cell therapies Abecma and Breyanzi along with multiple sclerosis and ulcerative colitis drug Zeposia especially stand out. Over the next few years, these and other drugs could help make up for anticipated sales declines for Revlimid.</p>\n<h2>2. <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a></h2>\n<p>Analysts look for an even better performance over the next 12 months from&nbsp;<b>Sanofi</b> (NASDAQ:SNY). The average price target for the French drugmaker is 35% above the current share price. The lowest target for Sanofi among the three analysts surveyed by Refinitiv expects the pharma stock to soar by at least 20%.</p>\n<p>Sanofi's partnership with <b>Regeneron</b>&nbsp;gives the company multiple growth drivers. Sales of Dupixent are skyrocketing and could pick up more momentum with the U.S. Food and Drug Administration's new restrictions on JAK inhibitors. Cancer drug Libtayo continues to gain steam with additional approved indications.</p>\n<p>Regeneron isn't helping Sanofi on every front, though. The big drugmaker has several products of its own with strong sales growth, including rare blood disorder drug Cablivi, type 2 diabetes drug Soliqua, and its vaccines franchise.</p>\n<p>Investors also get an added bonus with Sanofi -- its dividend. The company's dividend yield currently tops 4%, which makes Sanofi one of the most attractive pharma stocks for income-seeking investors.</p>\n<h2>3. Vertex Pharmaceuticals</h2>\n<p>Wall Street is especially enthusiastic about the prospects for&nbsp;<b>Vertex Pharmaceuticals</b> (NASDAQ:VRTX). The consensus price target for the stock is nearly 41% above the current share price. Twenty-two of the 27 analysts surveyed by Refinitiv view Vertex as a buy or strong buy with the other two analysts recommending holding the stock.</p>\n<p>The primary reason behind this bullishness is Vertex's cystic fibrosis (CF) franchise. There are only four approved CF drugs in the U.S. and Europe that treat the underlying cause of the genetic disease. Vertex markets all of them. The company's CF drugs should be able to generate even higher sales as Vertex picks up additional reimbursement deals and regulatory approvals.</p>\n<p>Vertex could have a non-CF drug on the market in the not-too-distant future. The company is partnering with <b>CRISPR Therapeutics</b>&nbsp;to develop gene-editing therapy CTX001 in treating rare blood disorders beta-thalassemia and sickle cell disease. Vertex and CRISPR Therapeutics hope to be able to file for regulatory approvals as soon as 2023.</p>\n<p>Other pipeline candidates could also provide catalysts for the stock. Vertex expects to report results from a phase 2 study evaluating VX-147 in treating APOL1-mediated focal segmental glomerulosclerosis (FSGS) later this year. Data from a phase 2 study of VX-548 in treating acute pain following bunionectomy surgery should be announced in early 2022.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Big Pharma Stocks Wall Street Thinks Could Soar By At Least 30%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Big Pharma Stocks Wall Street Thinks Could Soar By At Least 30%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-28 23:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/28/3-big-pharma-stocks-wall-street-thinks-could-soar/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Many investors like to buy shares of large drugmakers for the relative stability that they provide. But tremendous growth often isn't expected from these stocks.\nThat doesn't mean, though, that strong...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/28/3-big-pharma-stocks-wall-street-thinks-could-soar/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BMY":"施贵宝","SNY":"赛诺菲安万特","VRTX":"福泰制药"},"source_url":"https://www.fool.com/investing/2021/09/28/3-big-pharma-stocks-wall-street-thinks-could-soar/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2170724186","content_text":"Many investors like to buy shares of large drugmakers for the relative stability that they provide. But tremendous growth often isn't expected from these stocks.\nThat doesn't mean, though, that strong growth is always out of the question for top biopharmaceutical companies. Here are three big pharma stocks that Wall Street thinks could soar by at least 30% within the next 12 months.\nImage source: Getty Images.\n1. Bristol Myers Squibb\nThe consensus Wall Street price target for Bristol Myers Squibb (NYSE:BMY) reflects a premium of nearly 34% to the current share price. Of the 22 analysts surveyed by Refinitiv, the most pessimistic of the group thinks that the pharma stock could jump at least 10% higher.\nThis bullishness might be somewhat surprising. BMS' top-selling product, Revlimid, faces generic competition beginning next year. The blood cancer drug generated 27% of the company's total revenue in the second quarter.\nSo why do analysts like BMS so much? For one thing, that generic competition will only be in limited volumes at first thanks to contractual agreements. The company also has several other blockbusters with strong sales growth, notably including blood thinner Eliquis and cancer immunotherapies Opdivo and Yervoy.\nBMS' lineup is loaded with newer drugs with tremendous potential as well. Cancer cell therapies Abecma and Breyanzi along with multiple sclerosis and ulcerative colitis drug Zeposia especially stand out. Over the next few years, these and other drugs could help make up for anticipated sales declines for Revlimid.\n2. Sanofi\nAnalysts look for an even better performance over the next 12 months from Sanofi (NASDAQ:SNY). The average price target for the French drugmaker is 35% above the current share price. The lowest target for Sanofi among the three analysts surveyed by Refinitiv expects the pharma stock to soar by at least 20%.\nSanofi's partnership with Regeneron gives the company multiple growth drivers. Sales of Dupixent are skyrocketing and could pick up more momentum with the U.S. Food and Drug Administration's new restrictions on JAK inhibitors. Cancer drug Libtayo continues to gain steam with additional approved indications.\nRegeneron isn't helping Sanofi on every front, though. The big drugmaker has several products of its own with strong sales growth, including rare blood disorder drug Cablivi, type 2 diabetes drug Soliqua, and its vaccines franchise.\nInvestors also get an added bonus with Sanofi -- its dividend. The company's dividend yield currently tops 4%, which makes Sanofi one of the most attractive pharma stocks for income-seeking investors.\n3. Vertex Pharmaceuticals\nWall Street is especially enthusiastic about the prospects for Vertex Pharmaceuticals (NASDAQ:VRTX). The consensus price target for the stock is nearly 41% above the current share price. Twenty-two of the 27 analysts surveyed by Refinitiv view Vertex as a buy or strong buy with the other two analysts recommending holding the stock.\nThe primary reason behind this bullishness is Vertex's cystic fibrosis (CF) franchise. There are only four approved CF drugs in the U.S. and Europe that treat the underlying cause of the genetic disease. Vertex markets all of them. The company's CF drugs should be able to generate even higher sales as Vertex picks up additional reimbursement deals and regulatory approvals.\nVertex could have a non-CF drug on the market in the not-too-distant future. The company is partnering with CRISPR Therapeutics to develop gene-editing therapy CTX001 in treating rare blood disorders beta-thalassemia and sickle cell disease. Vertex and CRISPR Therapeutics hope to be able to file for regulatory approvals as soon as 2023.\nOther pipeline candidates could also provide catalysts for the stock. Vertex expects to report results from a phase 2 study evaluating VX-147 in treating APOL1-mediated focal segmental glomerulosclerosis (FSGS) later this year. Data from a phase 2 study of VX-548 in treating acute pain following bunionectomy surgery should be announced in early 2022.","news_type":1},"isVote":1,"tweetType":1,"viewCount":466,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":14,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}

3 Big Pharma Stocks Wall Street Thinks Could Soar By At Least 30%

评论（3）

热议股票